Current therapies in Hodgkin's disease


DOI: 10.1007/s00259-003-1156-7

Cite this article as:
Kogel, K.E. & Sweetenham, J.W. Eur J Nucl Med Mol Imaging (2003) 30(Suppl 1): S19. doi:10.1007/s00259-003-1156-7


Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.


Hodgkin's disease Treatment Early-stage disease Long-term toxicity 

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  1. 1.Division of Medical OncologyUniversity of Colorado Health Sciences CentreDenverUSA

Personalised recommendations